SK4382001A3 - Mglur5 antagonists for the treatment of pain and anxiety - Google Patents
Mglur5 antagonists for the treatment of pain and anxiety Download PDFInfo
- Publication number
- SK4382001A3 SK4382001A3 SK438-2001A SK4382001A SK4382001A3 SK 4382001 A3 SK4382001 A3 SK 4382001A3 SK 4382001 A SK4382001 A SK 4382001A SK 4382001 A3 SK4382001 A3 SK 4382001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- antagonist
- mglur
- pain
- mglur5
- treatment
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 58
- 208000002193 Pain Diseases 0.000 title claims abstract description 33
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 18
- 230000036506 anxiety Effects 0.000 title claims abstract description 18
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims abstract description 52
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims abstract description 52
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims abstract description 37
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims abstract description 37
- 229940124807 mGLUR antagonist Drugs 0.000 claims abstract description 26
- 230000002093 peripheral effect Effects 0.000 claims abstract description 15
- 230000003993 interaction Effects 0.000 claims abstract description 13
- 230000000202 analgesic effect Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 210000003169 central nervous system Anatomy 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 206010065390 Inflammatory pain Diseases 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000008499 blood brain barrier function Effects 0.000 claims description 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 25
- 241000700159 Rattus Species 0.000 description 14
- MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- -1 cyano, ethynyl Chemical group 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 230000003040 nociceptive effect Effects 0.000 description 6
- HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 5
- 208000035154 Hyperesthesia Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000003070 anti-hyperalgesia Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 230000000917 hyperalgesic effect Effects 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- DDOQBQRIEWHWBT-VKHMYHEASA-N (2S)-2-amino-4-phosphonobutanoic acid Chemical compound OC(=O)[C@@H](N)CCP(O)(O)=O DDOQBQRIEWHWBT-VKHMYHEASA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- GQSLKBHGURRQLG-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-6-methylpyridine Chemical compound CC1=CC=CC(C#CC=2C=C(F)C=CC=2)=N1 GQSLKBHGURRQLG-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 238000011795 OF1 mouse Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000011273 social behavior Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000005477 standard model Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- QFKXUDHGSXTPAU-UHFFFAOYSA-N 2-methyl-6-(2-pyridin-3-ylethenyl)pyridine Chemical compound CC1=CC=CC(C=CC=2C=NC=CC=2)=N1 QFKXUDHGSXTPAU-UHFFFAOYSA-N 0.000 description 1
- KYJSGWVPWUBKGL-UHFFFAOYSA-N 2-methyl-6-(2-pyridin-3-ylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=NC=CC=2)=N1 KYJSGWVPWUBKGL-UHFFFAOYSA-N 0.000 description 1
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 1
- OONJJBQNBKMFFT-UHFFFAOYSA-N 2-methyl-6-[2-(2,3,5-trichlorophenyl)ethynyl]pyridine Chemical compound CC1=CC=CC(C#CC=2C(=C(Cl)C=C(Cl)C=2)Cl)=N1 OONJJBQNBKMFFT-UHFFFAOYSA-N 0.000 description 1
- ANUFAWHRSIJTHW-UHFFFAOYSA-N 2-methylheptanedioic acid Chemical compound OC(=O)C(C)CCCCC(O)=O ANUFAWHRSIJTHW-UHFFFAOYSA-N 0.000 description 1
- GINVUTIGCMRSDL-VOTSOKGWSA-N 3-[2-[(e)-2-(3,5-dichlorophenyl)ethenyl]-6-methylpyridin-3-yl]oxy-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C)N=C1\C=C\C1=CC(Cl)=CC(Cl)=C1 GINVUTIGCMRSDL-VOTSOKGWSA-N 0.000 description 1
- ODIHLEYTPVYAPY-UHFFFAOYSA-N 3-[2-fluoro-4-[[3-[2-methyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methylamino]phenyl]propanoic acid Chemical compound CC1=CC(OCCCS(C)(=O)=O)=CC=C1C1=CC=CC(CNC=2C=C(F)C(CCC(O)=O)=CC=2)=C1 ODIHLEYTPVYAPY-UHFFFAOYSA-N 0.000 description 1
- VTMJKPGFERYGJF-ZETCQYMHSA-N 4-[(s)-amino(carboxy)methyl]benzoic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(C(O)=O)C=C1 VTMJKPGFERYGJF-ZETCQYMHSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920004011 Macrolon® Polymers 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 1
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 1
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 101001032838 Rattus norvegicus Metabotropic glutamate receptor 5 Proteins 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010039670 Sciatic nerve injury Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- LOCPVWIREQIGNQ-UHFFFAOYSA-N chembl88553 Chemical compound CC1=CC=C(O)C(N=NC=2C=CC=CC=2)=N1 LOCPVWIREQIGNQ-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013291 male lister hooded rat Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 1
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 1
- 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000003572 second messenger assay Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- SISOFUCTXZKSOQ-ZHACJKMWSA-N sib-1893 Chemical compound CC1=CC=CC(\C=C\C=2C=CC=CC=2)=N1 SISOFUCTXZKSOQ-ZHACJKMWSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9821503.1A GB9821503D0 (en) | 1998-10-02 | 1998-10-02 | Organic compounds |
US22081398A | 1998-12-23 | 1998-12-23 | |
PCT/EP1999/007239 WO2000020001A1 (en) | 1998-10-02 | 1999-09-30 | Mglur5 antagonists for the treatment of pain and anxiety |
Publications (1)
Publication Number | Publication Date |
---|---|
SK4382001A3 true SK4382001A3 (en) | 2001-08-06 |
Family
ID=26314451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK438-2001A SK4382001A3 (en) | 1998-10-02 | 1999-09-30 | Mglur5 antagonists for the treatment of pain and anxiety |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1117403B1 (pt) |
JP (1) | JP2002526408A (pt) |
KR (1) | KR20010088832A (pt) |
CN (1) | CN1187048C (pt) |
AT (1) | ATE255894T1 (pt) |
AU (1) | AU765644B2 (pt) |
BR (1) | BR9914215A (pt) |
CA (1) | CA2345137A1 (pt) |
DE (1) | DE69913548T2 (pt) |
DK (1) | DK1117403T3 (pt) |
ES (1) | ES2213389T3 (pt) |
HU (1) | HUP0200553A3 (pt) |
ID (1) | ID29095A (pt) |
IL (2) | IL142047A0 (pt) |
NO (1) | NO20011440L (pt) |
NZ (1) | NZ510743A (pt) |
PL (1) | PL202906B1 (pt) |
PT (1) | PT1117403E (pt) |
RU (1) | RU2232017C2 (pt) |
SK (1) | SK4382001A3 (pt) |
WO (1) | WO2000020001A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0005700D0 (en) * | 2000-03-09 | 2000-05-03 | Glaxo Group Ltd | Therapy |
CA2432077C (en) | 2000-12-22 | 2011-01-18 | F. Hoffmann-La Roche Ag | Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
SE0303419D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 11 |
SE0303418D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 1 |
FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
DE102005062985A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln |
CA2670116C (en) | 2006-11-22 | 2015-03-10 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
US20110294879A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
WO2012054724A1 (en) | 2010-10-21 | 2012-04-26 | Massachusetts Institute Of Technology | Methods of treating seizure disorders |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
EP2557183A1 (de) | 2011-08-12 | 2013-02-13 | Siemens Aktiengesellschaft | Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
CN107849006B (zh) | 2015-06-03 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
WO2019025931A1 (en) | 2017-07-31 | 2019-02-07 | Novartis Ag | USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE |
EP3459939A1 (en) | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
-
1999
- 1999-09-30 ID IDW20010730A patent/ID29095A/id unknown
- 1999-09-30 NZ NZ510743A patent/NZ510743A/en unknown
- 1999-09-30 EP EP99948905A patent/EP1117403B1/en not_active Revoked
- 1999-09-30 DE DE69913548T patent/DE69913548T2/de not_active Revoked
- 1999-09-30 KR KR1020017004152A patent/KR20010088832A/ko not_active Application Discontinuation
- 1999-09-30 HU HU0200553A patent/HUP0200553A3/hu unknown
- 1999-09-30 AU AU61984/99A patent/AU765644B2/en not_active Ceased
- 1999-09-30 JP JP2000573360A patent/JP2002526408A/ja active Pending
- 1999-09-30 PT PT99948905T patent/PT1117403E/pt unknown
- 1999-09-30 AT AT99948905T patent/ATE255894T1/de active
- 1999-09-30 BR BR9914215-5A patent/BR9914215A/pt not_active Application Discontinuation
- 1999-09-30 CA CA002345137A patent/CA2345137A1/en not_active Abandoned
- 1999-09-30 CN CNB998117110A patent/CN1187048C/zh not_active Expired - Fee Related
- 1999-09-30 SK SK438-2001A patent/SK4382001A3/sk unknown
- 1999-09-30 IL IL14204799A patent/IL142047A0/xx active IP Right Grant
- 1999-09-30 WO PCT/EP1999/007239 patent/WO2000020001A1/en not_active Application Discontinuation
- 1999-09-30 ES ES99948905T patent/ES2213389T3/es not_active Expired - Lifetime
- 1999-09-30 PL PL346876A patent/PL202906B1/pl not_active IP Right Cessation
- 1999-09-30 RU RU2001111868/14A patent/RU2232017C2/ru not_active IP Right Cessation
- 1999-09-30 DK DK99948905T patent/DK1117403T3/da active
-
2001
- 2001-03-15 IL IL142047A patent/IL142047A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011440A patent/NO20011440L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CA2345137A1 (en) | 2000-04-13 |
AU765644B2 (en) | 2003-09-25 |
HUP0200553A2 (hu) | 2002-07-29 |
NO20011440D0 (no) | 2001-03-21 |
ID29095A (id) | 2001-07-26 |
RU2232017C2 (ru) | 2004-07-10 |
NO20011440L (no) | 2001-05-15 |
CN1187048C (zh) | 2005-02-02 |
BR9914215A (pt) | 2001-07-03 |
CN1321087A (zh) | 2001-11-07 |
KR20010088832A (ko) | 2001-09-28 |
DE69913548D1 (de) | 2004-01-22 |
PL346876A1 (en) | 2002-03-11 |
HUP0200553A3 (en) | 2002-11-28 |
DE69913548T2 (de) | 2004-09-23 |
JP2002526408A (ja) | 2002-08-20 |
EP1117403B1 (en) | 2003-12-10 |
PT1117403E (pt) | 2004-04-30 |
WO2000020001A1 (en) | 2000-04-13 |
PL202906B1 (pl) | 2009-08-31 |
IL142047A0 (en) | 2002-03-10 |
EP1117403A1 (en) | 2001-07-25 |
NZ510743A (en) | 2003-10-31 |
ATE255894T1 (de) | 2003-12-15 |
DK1117403T3 (da) | 2004-04-13 |
IL142047A (en) | 2007-09-20 |
ES2213389T3 (es) | 2004-08-16 |
AU6198499A (en) | 2000-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK4382001A3 (en) | Mglur5 antagonists for the treatment of pain and anxiety | |
CA2336822C (en) | Method of treatment and pharmaceutical composition | |
SK88897A3 (en) | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine | |
KR20170003527A (ko) | 경구 투여용 펜토산 폴리설페이트 염의 조성물 | |
JP2009504737A (ja) | 脈管疾患の治療又は予防のためのpar−1/par−4阻害剤の使用 | |
US11389435B2 (en) | Compositions and methods for treating epilepsy | |
US20010056084A1 (en) | MGluR5 antagonists for the treatment of pain and anxiety | |
EP2205231A1 (en) | Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound | |
JP2007529556A (ja) | 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびn−メチル−d−アスパラギン酸拮抗剤 | |
Li et al. | Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I2 receptor ligands | |
US20070265279A1 (en) | Use of mGluR5 antagonists for the treatment of pruritic conditions | |
JP2002526408A5 (pt) | ||
PT1799199E (pt) | Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica | |
US8455548B2 (en) | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists | |
PT1003494E (pt) | ( d ) -metadona, um analgésico não opióide. | |
CZ298398A3 (cs) | Farmaceutický přípravek | |
CZ2003234A3 (cs) | 2-Aryl-8-oxodihydropurinové deriváty jako léčivo | |
US20130137725A1 (en) | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists | |
Rodger | The anticonvulsant profiles of two calcium channel antagonists in animal models of epilepsy | |
Shepherd | Investigational Drugs for the Treatment of Hypertension | |
CA2772354A1 (en) | Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists | |
MXPA00009464A (en) | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |